Skip to main content
ASHI 50th Annual Meeting Mobile App Main banner
Back

Paul Keown, MD, DSc, MBA, FACP, FASN, FAST, FRCP, FRCPC, FRCPath, FRSC, FRSB

University of British Columbia

Paul Keown (UBC Medicine), a specialist in immunology and transplantation, is a Professor in UBC’s Department of Medicine and a practicing physician at Vancouver General Hospital. He has served as the Executive Director of the BC Transplantation Program, President of the Canadian Transplantation Society and as Head of the Division of Nephrology (2004-2009). Currently he is the Director of the Vancouver General Hospital Immunology Laboratory, the Lead for the Precision Medicine in Transplantation UBC Research Excellence Cluster, and the Lead for Genome Canada Transplant Consortium (2018-2025).

Dr. Paul Keown received his training in medicine, immunobiology and transplantation at the universities of Manchester, Paris and Western Ontario, his research doctorates in medicine and science from the University of Manchester, and his MBA from Simon Fraser University. During his decades long career his principal research activities have focused particularly on the immune response in transplantation and autoimmune disease, and extend from molecular genetics to healthcare economics.

Over his career Dr. Keown has contributed to the fields of immunopharmacology, immunogenetics, immunotherapeutics, molecular genetics and proteomics with 500+ visiting professorships, plenary addresses, or invited lectures, over 350 published abstracts and more than 400 scientific manuscripts, editorials and book chapters.

His corporate responsibilities include Founder and Director of Syreon Corporation (N.A.) and Syreon Research Institute (E.U.), specializing in the application of advanced information and computational sciences for personalized medicine in complex diseases. His focus is global corporate direction and strategic development; technology innovation and application, and direction of biostatistics and computational sciences.

Disclosure information not submitted.

Presentation(s):